Karo Pharma AB – Strategy, SWOT and Corporate Finance Report

Karo Pharma AB – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360Ëš view of the company

Key Highlights

Karo Pharma AB (Karo Pharma), formerly Karo Bio AB, is a health care company that focuses on research and development of pharmaceutical products in the areas of cancer and autoimmune diseases. Its key research area involves nuclear receptors as target proteins for the development of new pharmaceuticals. Karo Pharma discovers drugs to target major diseases including autoimmune diseases such as multiple sclerosis; and multiple types of cancer, viral and bacterial infections. The company’s projects are based on ROR gamma receptor and estrogen receptor. Its development pipeline also includes T268A Cold Spray which utilizes glucose oxidase enzyme in combination with glucose to fight against cold virus. Karo Pharma is headquartered in Huddinge, Stockholm, Sweden.

Scope

Detailed information on Karo Pharma AB required for business and competitor intelligence needs

A study of the major internal and external factors affecting Karo Pharma AB in the form of a SWOT analysis

An in-depth view of the business model of Karo Pharma AB including a breakdown and examination of key business segments

News about Karo Pharma AB, such as business expansion, restructuring, and contract wins

Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

Gain understanding of Karo Pharma AB and the factors that influence its strategies.

Track strategic initiatives of the company and latest corporate news and actions.

Assess Karo Pharma AB as a prospective partner, vendor or supplier.

Support sales activities by understanding your customers' businesses better.

Stay up to date on Karo Pharma ABs business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

Nuevolution AB

Meda AB

Genmab A/S

Dyax Corp

BioInvent International AB

Active Biotech AB

Table of Contents

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

Karo Pharma AB - Key Facts

Karo Pharma AB - Key Employees

Karo Pharma AB - Key Employee Biographies

Karo Pharma AB - Major Products and Services

Karo Pharma AB - History

Karo Pharma AB - Company Statement

Karo Pharma AB - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2 Company Analysis

Company Overview

Karo Pharma AB - Business Description

Business Segment: OTC (Over the counter) products

Overview

Performance

Business Segment: Other health related products

Overview

Performance

Business Segment: Rx (prescription pharmaceuticals)

Overview

Performance

Geographical Segment: Denmark

Performance

Geographical Segment: Europe

Performance

Geographical Segment: Finland

Performance

Geographical Segment: Iceland

Performance

Geographical Segment: Norway

Performance

Geographical Segment: Rest of world

Performance

Geographical Segment: Sweden

Performance

Geographical Segment: US

Performance

R&D Overview

Karo Pharma AB - Corporate Strategy

Karo Pharma AB - SWOT Analysis

SWOT Analysis - Overview

Karo Pharma AB - Strengths

Karo Pharma AB - Weaknesses

Karo Pharma AB - Opportunities

Karo Pharma AB - Threats

Karo Pharma AB - Key Competitors

Section 3 Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 Company’s Lifesciences, Oil & Gas Financial Deals and Alliances

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Karo Pharma AB, Recent Deals Summary

Section 5 Company’s Recent Developments

Aug 14, 2019: Jon Johnsson appointed new CFO of Karo Pharma

Jul 19, 2019: Karo Pharma: Interim report January June 2019

Jul 19, 2019: Clarification of the statement in the interim report published 19 July 2019 regarding the rights issue with pre-emptive rights

Apr 26, 2019: Karo Pharma: Interim report the first quarter 2019

Apr 03, 2019: Karo Pharma Aktiebolag names Christoffer Lorenzen as CEO

Feb 14, 2019: Karo Pharma: Year end report 2018

Jul 19, 2018: Karo pharma triples sales and profit in the second quarter

Apr 26, 2018: Karo Pharma Doubles Sales and Earnings in the First Quarter

Mar 23, 2018: Karo Pharma Supports Operation Smile

Feb 22, 2018: Karo Pharma: Year-end Report 2017

Section 6 Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List of Tables

List of Tables

Karo Pharma AB, Key Facts

Karo Pharma AB, Key Employees

Karo Pharma AB, Key Employee Biographies

Karo Pharma AB, Major Products and Services

Karo Pharma AB, History

Karo Pharma AB, Subsidiaries

Karo Pharma AB, Key Competitors

Karo Pharma AB, Ratios based on current share price

Karo Pharma AB, Annual Ratios

Karo Pharma AB, Annual Ratios (Cont…1)

Karo Pharma AB, Annual Ratios (Cont…2)

Karo Pharma AB, Interim Ratios

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Karo Pharma AB, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

List of Figures

List of Figures

Karo Pharma AB, Performance Chart (2014 – 2018)

Karo Pharma AB, Ratio Charts

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@marketline.com
+44 (0) 161 359 5817

Saved reports